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Background: The mechanism behind poor survival of acute myeloid leukemia (AML) patients with
1-barabinofuranosylcytosine (Ara-C) based treatment remains unclear. This study aimed to assess the pharmacogenomic
effects of Ara-C metabolic pathway in patients with AML.
Methods: The genotypes of 19 single nucleotide polymorphisms (SNPs) of DCK, CDA and SLC29A1from 100 AML
patients treated with Ara-C were examined. All the SNPs were screened with ligase detection reaction assay. The
transcription analysis of genes was examined by quantitative real time polymerase chain reaction. The association
between clinical outcome and gene variants was evaluated by Kaplan-Meier method.
Results: Genotypes of rs9394992 and rs324148 for SLC29A1 in remission patients were significantly different from
those in relapsed ones. Post-induction overall survival (OS) significantly decreased in patients with the CC genotype of
rs324148 compared with CT and TT genotypes (hazard ratio [HR] = 2.997 [95% confidence interval (CI): 1.71-5.27]). As
compared with CT and TT genotype, patients with the CC genotype of rs9394992 had longer survival time (HR = 0.25
[95% CI: 0.075-0.81]; HR = 0.43 [95% CI: 0.24-0.78]) and longer disease-free survival (DFS) (HR = 0.52 [95% CI: 0.29-0.93];
HR = 0.15 [95% CI: 0.05-0.47]) as well As compared with CT and TT genotype, patients with the CC genotype of
rs324148 had shorter DFS (HR = 3.18 [95% CI: 1.76-5.76]). Additionally, patients with adverse karyotypes had shorter DFS
(HR = 0.17 [95% CI: 0.05-0.54]) and OS (HR = 0.18 [95% CI: 0.05-0.68]).
Conclusions: AML patients with low activity of SLC29A1 genotype have shorter DFS and OS in Ara-C based therapy.
Genotypes of rs9394992 and rs324148 may be independent prognostic predictors for the survival of AML patients.
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Acute myeloid leukemia (AML), a heterogeneous disease
with various clinical presentations, can be treated with
1-barabinofuranosylcytosine (Ara-C) or Ara-C combined
with anthrocycline [1-3]. Despite the big progress in
respect to the improved remission rate of a majority of
patients (50-60%) under 60 years old, the outcome of
Ara-C based treatment is still unsatisfactory as 30-80%* Correspondence: chenfangyuan62@163.com
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unless otherwise stated.of patients relapse eventually after remission [4]. Be-
sides, long-term survival rates continue to be around
30% to 40% for adults, and treatment of patients with
relapsed or refractory AML with Ara-C based chemo-
therapy is unable to produce a prolonged leukemia-
free survival in most patients [4,5]. The mechanism
behind poor survival of AML patients with Ara-C
based treatment still remains unclear.
The cytotoxic effect of Ara-C needs metabolic activation
following transport into the cells. When administered in
standard doses, Ara-C is transported into cells via mem-
brane transporters including the solute carrier family 29d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of AML patients
Characteristics
P
n n % Median (range)
Gender (Male/female) 100 42/58 42/58
Age (years) 100 43 (17–76)
Bone marrow blasts (%) 92 67.3 (37.5-97)
WBC count (x109/L) 95 17.9 (2.5-193.9)
FAB classification 100
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High-dose Ara-C diffuses into the cell at a rate higher
than that of pump-mediated transport [6,7]. Inside the
cell, Ara-C is converted to its active triphosphate form
(Ara-CTP) through a series of phosphorylation actions
mediated by deoxycytidine kinase (DCK), deoxycytidylate
kinase and nucleoside diphosphate kinase (NDPK) [8,9]
(Figure 1). DCK is the rate-limiting enzyme in this
process. Ara-CTP plays its cytotoxic role by incorpor-
ating into DNA to inhibit DNA synthesis in a competitive
way, resulting in leukemic cell death [10-13]. Cytoplasmic
5’-nucleotidase (5-NT) dephosphorylates Ara-CMP, a
key intermediate, to prevent accumulation of Ara-CTP,
which might reduce cellular sensitivity to the cytotoxic
activity of Ara-C [14]. CDA can catalyze the hydrolytic
deamination of Ara-C to its inactive metabolite 1-B-D-
arabinofuranosyluracil (Ara-U). Ribonucleotide reduc-
tase (RRM), which consists of 2 subunits, could decrease
Ara-C cytotoxycity by catalyzing the de novo synthesis of
dNTP which could inhibit the function of DCK [15-18].
Genes involved in Ara-C transport and metabolism,
and the potential mechanisms of Ara-C resistance, are
investigated in the previous studies. DCK can be inhib-
ited by increased dCTP pool through a negative feed-
back, and increased CDA function leads to increase in
the deamination of Ara-C to AraU [19-21]. Decreased
Ara-C transport over the cell membrane into the cyto-
plasm [6,22] or inactivation of DCK [23,24] can both off-
set the cytotoxic function of Ara-C. Our previous study
showed continuous exposure to Ara-C could induce
drug resistance with decreased transcription level of
DCK and SLC29A1 as well as elevated mRNA expres-
sion of CDA (data not shown). Genetic variations, par-
ticularly SNPs, have been identified in these genes
involved in Ara-C transport and metabolism [25-27].
Both in vivo and in vitro studies demonstrated that the
activities of these enzymes are correlated with poly-
morphic gene variations [28,29], and some of these SNPsFigure 1 Schematic description of Ara-C transport and metabolism.
The asterisked letters indicate genes examined in this study.are even highly correlated with treatment response and
survival of AML patients with Ara-C based chemo-
therapy [30-33]. Previous study found that rs329491 of
SLC29A1 maybe a favorable survival factor for pa-
tients with pancreatic cancer [34]. Another study also
showed that rs9394992 may be associated with the
survival of patients with non-small cell lung cancer
[35]. However, none of these SNPs have been reported
in leukemia patients.
To investigate the possible involvement of genes cor-
relating with Ara-C transport and metabolism in pa-
tients with chemotherapy-resistant AML, we assessed
the pharmacogenomic effects of Ara-C metabolic/trans-
port pathway in AML in this study.
Results
Patients’ characteristics and treatment outcomes
Baseline characteristics and treatment results of the 100
AML patients were summarized in Table 1. A total of 51
patients (54.8%) were of normal karyotype. Among the
patients who were available for their cytogenetic or mo-
lecular information, 14 patients had t (8; 21) (q22; q22).
Of the 93 patients detected, 8 patients carried NPM1
mutation, and 5 patients with FLT3 internal tandem du-
plication (ITD) mutation were identified in 92 patients.
The median and mean follow-up duration were 44 and
37.8 months, respectively. 74% (n = 74) of patients
achieved remission after one cycle (n = 69) or two cycles









NPM1 93 8/85 8.6/91.4
Positive/negative
FLT-ITD 92 5/87 5.4/94.6
Positive/negative
FAB, French-American-British.
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(35.7 ± 2.4)%, and (43.2 ± 2.2)%, respectively.Transcription level of genes involving in Ara-C transport
and metabolism
To detect the transcription of DCK, CDA and SLC29A1,
we examined mRNA expression of these genes in the
leukemia blasts from the bone marrow of AML patients.
The results showed that the RNA expression of DCK
and SLC27A1in patients with complete remission was
higher than that of non-remission ones, while CDA ex-
pression in the remission patients was lower than that
of non-remission ones (Figure 2). The similar results
was identified in our previous in-vitro study as well
(Additional file 1c).Genotype frequencies of DCK, CDA and SLC29A1
polymorphisms
19 SNPs (Table 2) of DCK, CDA and SLC29A1 were
screened in 100 AML patients and 100 healthy controls,
and their genotype frequencies and allele frequencies
were summarized (Additional file 2). SNP15 was ex-
cluded from analysis since only one genotype was identi-
fied in the AML patients and normal healthy controls.
Genotype frequencies of the other 18 SNPs were identi-
fied in Hardy-Weinberg equilibrium (χ2 = 0.002-3.590,
P = 0.580-0.960). No difference of genotype and allele
frequencies of all the 18 SNPs were found between the
AML patients and the healthy controls. Genotype fre-
quencies were not significantly different between male
and female AML patients. No significant correlation
was observed between other AML prognostic factors
including WBC at presentation, age or cytogenetic ab-
normalities, and genotypes of SLC29A1 polymorphic
variants. The two SNPs of SLC29A1b, rs324148 and
rs9394992, were not in strong linkage disequilibrium
(LD) (D’ = 0.73, r2 = 0.11) in CHB as well as LD and
CEU (D’ = 0.38, r2 = 0.03) (Figure 3a, b).Figure 2 The mRNA expression of genes related to Ara-C efficacy
in AML. Gene expression levels of DCK, CDA, and SLC29A1 were
analyzed by quantitative RT-PCR. β-actin was used as an internal
control. *#$ indicated statistically significant (P < 0.05).Impact of SNP genotypes on treatment response
To identify the correlation between genotypes of SNPs
with Ara-C based treatment response, all 19 SNPs were
screened. The results showed that genotype frequency of
genotype CC in SNP16 was higher in relapsed patients,
while frequencies of CT and TT were higher in remis-
sion ones (P = 0.04). For SNP18, more genotype fre-
quency of genotype CC was found in remission patients,
while higher frequencies of genotype CT and TT were
found in relapsed ones (P = 0.0004) (Figure 4a, b).
Impact of genotypes of rs9394992 and rs324148 on
SLC29A1 transcription
To further investigate the effect of different genotypes of
polymorphic varies on the transcription of SLC29A1, we
evaluated the mRNA expression of the rs9394992 and
rs324148 of SLC29A1 in AML patients. Higher mRNA
expression of genotype TT was observed in rs324148, as
compared to that of genotype CC (P < 0.01). Higher ex-
pression of genotype CC was observed in rs9394992 com-
pared with genotype CT and TT (P < 0.01) (Figure 4c),
which indicated that SNPs might modify Ara-C toxicity
through transcription regulation.
The effect of SNPs on Ara-C based treatment outcomes
Univariate analysis found that SNP18 (rs9394992) and
SNP16 (rs324148) of SLC29A1, were significant prog-
nostic factors to OS and DFS (Figure 5). The CC geno-
type of SNP16 was significantly associated with shorter
overall survival time compared to the CT and TT geno-
types (hazard ratio [HR] = 2.997 [95% confidence interval
(CI): 1.71-5.27], P = 0.0001) (Figure 5a). The genotype of
CC in SNP18 was significantly associated with longer sur-
vival time compared to CT (HR = 0.25 [95% CI: 0.075-
0.81], P = 0.02) or TT genotypes (HR = 0.43 [95% CI: 0.24-
0.78], P = 0.005) (Figure 5c). This association was more
significant in patients with both genotype CC of rs324148
and genotype CT +TT of rs9394992 (Figure 6a).
The CC genotype of SNP16 was significantly associ-
ated with shorter DFS compared to the CT and TT
genotypes (HR = 3.18 [95% CI: 1.76-5.76], P = 0.0001)
(Figure 5b). Genotype of CC of SNP18 was associated
with longer DFS compared to CT (HR = 0.52 [95% CI:
0.29-0.93], P = 0.03) or TT genotypes (HR = 0.15 [95%
CI: 0.05- 0.47], P = 0.001) (Figure 5d). This association
was more significant in patients with both genotype CC of
rs324148 and genotype CT + TT of rs9394992 (Figure 6b).
Impact of other variables on Ara-C based treatment
outcomes
No effects of age, gender and FAB subtypes on the DFS
and OS of AML patients were identified (Additional file 3),
whereas adverse cytogenetic abnormalities indicated poorer
prognosis. However, no difference of DFS and OS was
Table 2 Characteristics of 19 SNPs
Gene SNP HGVS Names ref SNP ID Global MAF Location Chromosome position
DCK SNP1 NM_000788.2:c.-201C > T rs2306744 0.060/130 exon 4:71859352
SNP2 NM_000788.2:c.207 + 9846A > G rs12648166 0.458/998 intron 4:71873745
SNP3 NM_000788.2:c.757-1205C > T rs4694362 0.467/1015 intron 4:71893864
SNP4 NM_000788.2:c.165C > T rs4643786 0.227/494 exon 4:71895260
SNP5 NM_000788.2:c.207 + 11338A > G rs7684954 0.197/430 intron 4:71875237
SNP6 NM_000788.2:c.666-346 T > C rs936869 0.196/426 intron 4:71892036
SNP7 NM_000788.2:c.92-1110 T > C rs3775289 0.193/419 intron 4:71862674
CDA SNP8 NM_000788.2:c.266 + 3264A > G rs1689924 0.482/1049 intron 1:20934796
SNP9 NM_000788.2:c.267-4159C > T rs572529 0.350/761 intron 1:20936176
SNP10 NM_000788.2:c.267-4087G > A rs477155 0.279/606 intron 1:20936248
SNP11 NM_000788.2:c.154 + 1015A > G rs818202 0.480/1045 intron 1:20916791
SNP12 NM_000788.2:c.155-7161G > A rs818199 0.386/840 intron 1:20924260
SNP13 NM_000788.2:c.266 + 1809G > A rs10916827 0.345/752 intron 1:20933341
SNP14 NM_000788.2:c.266 + 2751G > A rs527912 0.349/759 intron 1:20934283
SNP15 NM_000788.2:c.208G > A rs60369023 0.002/4 exon 1:20931474
SLC29A1 SNP16 NM_001078174.1:c.30-549 T > C rs324148 0.228/496 intron 6:44196578
SNP17 NM_001078174.1:c.1260-201A > G rs760370 0.344/750 intron 6:44200953
SNP18 NM_001078174.1:c.29 + 913C > T rs9394992 0.290/631 intron 6:44195992
SNP19 NM_001078174.1:c.-54-3077A > G rs693955 0.189/411 intron 6:44191920
SNP, single-nucleotide polymorphism; rfID., reference SNP identification; HGVS Names, Human Genome Variation Societyname; MAF, minor allele frequency.
Figure 3 SLC29A1 Haplotype structure. The haplotype structure of SLC29A1 was generated based on HapMap Phase II + III Release 27 data.
Colors ranging from bright red to light red to white indicate the range of r2 values from high to low. The link of rs9394992 to rs324148 that we
identified in the survival analysis for AML patients is in the white (a) or light red box (b) with r2 < 0.5. CHB: Han Chinese in Beijing, China. CEU:
Utah residents with Northern and Western European ancestry from CEPH collection.
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Figure 4 Genotype frequencies of SNP16 (rs324148) and SNP18 (rs9394992) in AML patients and healthy control, and their impact on
the mRNA expression of SLC29A1. a, genotype frequencies of SNP16 (rs324148) in remission and relapsed patients, and in healthy control.
Frequency of genotype CC was higher in relapsed patients than those of CT and TT (P = 0.04); b, genotype frequencies of SNP18 (rs9394992) in
remission and relapsed patients, and in healthy control. Frequencies of genotype CT and TT were higher in relapsed patients than those of CC
(P = 0.0004). No difference of genotype frequencies of both SNPs was observed between healthy control and remission patients. c, relative
mRNA expression of SLC29A1 in patients with different genotypes of SNP16 and SNP18 by quantitative real time PCR, β-actin was used as
an internal control. *# + $^ indicated statistically significant (P < 0.05).
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abnormalities (Figure 7).
Discussion
It has been demonstrated in the previous studies that cyto-
genetics and molecular abnormalities were independentFigure 5 Univariate analysis of survival rates based on genotypes of
of AML, b: effect of SNP16 on DFS of AML; c, effect of SNP18 on OS of AMpredictors for the prognosis of AML patients [36-38].
However, in our study, adverse cytogenetic abnormalities
only accounted for 8.6% (n = 93) of patients. The majority
of patients was with intermediate and favorable cytogenet-
ics and showed no difference in survival. As Ara-C forms
the backbone of the treatment regimen, understanding theSNP16 (rs324148) and SNP19 (rs9394992). a: effect of SNP16 on OS
L; d, effect of SNP18 on DFS of AML.
Figure 6 Effect of SNP-SNP interactions on OS and DFS of patients with AML. a, combined effects of SNP16 and SNP18 on OS of patients
with AML; b, combined effects of SNP16 and SNP18 on DFS of patients with AML.
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help dissection of AML with distinct prognosis, so as to
individualize chemotherapy and potentially improve the
outcomes of AML patients.
In our study, we observed single SNP and SNP-SNP in-
teractions in the Ara-C transport pathway, which could
account for the interpatient variability of treatment out-
comes in AML patients. When tested independently, both
SNP rs324148 and rs9394992 in the SLC29A1gene con-
tributed to Ara-C resistance in patients with AML who re-
ceived Ara-C based treatment, and they were also significant
prognostic factors for survival of these patients. The geno-
types of these two SNPs showed various mRNA expressions,
which may be responsible for varied response to Ara-C
treatment. Although the SNPs in our study located in the in-
tron region of SLC29A1, they affected mRNA expression,
which might be due to direct regulation of transcription by
altering RNA elongation, splicing or maturation [39-41].
SLC29A1 was expressed in 83% of the AML patients
[6]. The results of the studies on the association between
SLC29A1 of human AML blasts and clinical drug re-
sponse were not consistent. Previous data showed that
there was no association between SLC29A1 and Ara-C
sensitivity [42]. However, some studies demonstrated close
correlation of SLC29A1 with Ara-C resistance, treatment
response and survival of patients with AML. The inhib-
ition of SLC29A1 expression may induce Ara-C resist-
ance; thereby reduce the overall survival of patients with
AML [6,43]. FLT3-ITD indicates poor prognosis in AML,Figure 7 Univariate analysis of cytogenetic abnormalities on DFS and
and DFS. a, Effects of cytogenetic abnormalities on DFS; b, Effects of cytog
NCCN guidelines version 2.2014 for AML (https://www.nccn.org).and one of the mechanisms involved was to suppress the
expression of SLC29A1 to induce Ara-C resistance in
AML patients [44].
Besides SLC29A1, other genes or mechanisms may be
responsible for Ara-C resistance. Previous in-vitro stud-
ies showed that the expression of DCK was correlated
with cellular sensitivity to Ara-C, while decreased DCK
activity was observed in Ara-C resistant cell lines
[24,45,46]. DCK and 5-NT mRNA expression in leu-
kaemic blasts at diagnosis was correlated with clinical
outcome [47], although no alterations in DCK expres-
sion and/or activity were observed in resistant and sen-
sitive AML patients [48]. Alternatively spliced forms of
DCK with reduced activity were found in Ara-C resist-
ant blasts [48,49], suggesting that DCK may contribute
to Ara-C resistance. Our study detected higher DCK
expression in leukemia blast in remission patients, but
failed to find any difference of polymorphisms between
remission and relapsed patients. CDA may be another
factor for Ara-C resistance. Elevated CDA activity was
correlated with Ara-C resistance [33,50]. CDA could
be an independent prognostic parameter for survival in
AML patients treated with Ara-C [27]. Other genes,
including 5-NT and RRM1 or RRM2, were also found
to be involved in Ara-C resistance [14,26,47,51,52].
Our study failed to detect the activity of SLC29A1A in
AML patients, in whom we inferred SLC29A1 activity
from genotype or mRNA expression correlated with
Ara-C sensitivity [43]. In addition, we could not differentiateOS of patients with AML. Effect of cytogenetic abnormalities on OS
enetic abnormalities on OS. Risk status was evaluated according to the
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nations of rs9394992 and rs324148, which might be due to
other SNPs. Studies showed DCK rs4694362 (CC genotype)
may be a poor prognostic factor for the OS of AML patients.
SLC29A1 rs3734703 (AA or AC genotype) together with
TYMS rs2612100 (AA genotype) were associated with
shorter relapse free survival (RFS) [31]. Polymorphisms
within the CDD gene also had an impact on the survival
of patients with AML [27]. In AML patients without
FLT3-ITD, variant allele of rs10883841 in 5-NT was asso-
ciated with shorter survival [26]. In addition, polymorphisms
of other genes were also identified to be responsible
for the prognosis of AML patients [53,54]. Therefore,
more parameters need to be included for better prog-
nostic stratification.
Interestingly, our previous study found that fludara-
bine (Flu) may restore the Ara-C sensitivity in AML
blasts (Additional file 1a,b) and increase the cytoxicity of
Ara-C (Additional file 1a), partially by increasing the
mRNA expression of DCK, SLC29A1, and decreasing
mRNA expression of CDA, RRM1 and RRM2 (Additional
file 1c). Clinical studies also suggested that Flu may
have a beneficial impact on the antileukemic efficacy
of Ara-C-based salvage therapy for relapsed and refrac-
tory AML [55,56].
In conclusion, cytogenetics might not be enough to
predict the prognosis of AML. Polymorphisms in genes
related to its Ara-C metabolism may serve as biomarkers
for Ara-C sensitivity, treatment response, and prognostic
markers in AML, thus individualize chemotherapy and
potentially improve outcomes of AML patients.
Materials and methods
Patients
From July 2004 to July 2009, 100 Asian Chinese adults
with de novo AML other than M3 were randomized to
receive low-dose cytarabine (100 mg/m2 intravenously
for 24 hours, given on day 1–7; n = 100) plus daunorubi-
cin (45 mg/m2 intravenously on day 1–3) or indarubicin
(10 mg/m2 intravenously on day 1–3). High-dose cytara-
bine (2 g/m2 intravenously over 3 hours, given every
12 hours on day 1–3; n = 27) was administered to pa-
tients for second cycle induction (n = 4) or for consolida-
tion. All patients were chemonaive at enrollment with
leukemia blasts > 70% in the bone marrow. Meanwhile,
100 healthy controls (media age: 46 years, range 14–84
years; n = 50 for male) were also included.
Subjects diagnosed with any other cancers or perni-
ciously administered cytotoxic drugs or radiation was
excluded. Primary bone marrow samples were collected
after informed consent was obtained from patients or
their guardians, in accordance with the Declaration of
Helsinki. This study was approved by the institutional
research board at Renji Hospital, Shanghai.SNP selection and genotyping
Three cytarabine transport and metabolism genes in-
cluding SLC29A1, DCK and CDA were reported to po-
tentially involve in the response to cytarabine. Based on
the database from NCBI (http://www.ncbi.nlm.nih.gov/)
and International Hap-Map project (http://hapmap.ncbi.
nlm.nih.gov/), 19 candidate SNPs in these genes were
initially selected.
Mononuclear cells (MNCs) were purified with Ficoll.
Genomic DNA was extracted from MNC samples using
standard methods recommended and normalized to
1 μg/μl. Quality and quantity of the extracted DNA
was checked on a Nanodrop ND-1000 UV–vis Spec-
trophotometer (NanoDrop Technologies, Wilmington,
DE, USA) by spectral absorption scans from 230 to
350 nm. Genotyping for the all genes’ polymorphism
was performed using ligase detection reaction (LDR)
assay following the manufacturer’s instructions. Gene-
specific polymerase chain reaction (PCR) primers and
fluorogenic probes for allelic discrimination were sup-
plied by Shanghai Generay Biotech. PCR cycling and
ligation reactions were performed in a GeneAmp PCR
System 9700 (Applied Biosystems, Foster City, CA) ac-
cording to the conditions specified by the manufacturer.
Ligation products were analyzed using ABI PRISM® 377
DNA Sequencer (Applied Biosystems, Foster City, CA).
Genotyping results were duplicated in 15% of samples
with 100% concordance between repeats.
Genomic DNA was extracted from peripheral blood
samples of 100 healthy donors using QIAamp blood
DNA isolation kits (Qiagen Sciences, Maryland, USA) as
per the manufacturer’s protocol. Genotyping was per-
formed as described for the patient population.
Real time PCR
0.5 × 106 leukemia cells were harvested, and total RNA
was extracted using the RNeasy Plus Mini kit (QIAGEN,
GmbH, Hilden, Germany) following the manufacturer’s
protocol. RNA quality and quantification were assessed
using the optical spectrometry 260/280 nm ratio. Subse-
quently, mRNA was reverse transcribed to cDNA using
Applied Biosystems High Capacity Reverse Transcription
kit (Applied Biosystems, Foster City, CA). Quantitative
RT-PCR was performed for DCK, CDA and SLC, with
β-actin as the internal control, using SYBR Premix Ex
Taqs (TaKaRa, Kyoto, Japan) on the Roche LightCycler®
480 system (Roche, Mannheim, Germany). Total reaction
was carried out in 10 μL volume, which consisted of 5 μL
SYBR Premix Ex Taqs Master Mix, 0.1 μL primers (final
of 10 nM forward and reverse primers), and 4 μL water,
along with 0.8 μL cDNA. The fast thermocycler parame-
ters were: 95°C for 10 seconds, and 40 cycles of 95°C for
5 second then 60°C for 30 seconds and 78°C for 1 second.
The qRT-PCR was run in triplicate and individual samples
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Definitions
Disease-free survival (DFS) was defined as time from re-
mission to failure at the end of two courses, relapse or
death of any cause. Overall survival (OS) was defined as
time from study entry to death of any cause. Complete
remission (CR) after induction chemotherapy was de-
fined as: (1) normal values for absolute neutrophil
(>1000/mcL) and platelet counts (≥100,000/mcL) inde-
pendent of transfusion; (2) less than 5% of blast cells,
no blasts with Auer rods on bone marrow examin-
ation; (3) absence of extramedullary leukemia. Partial
remission (PR) was defined as decrease of at least 50%
in the percentage of blasts to 5-25% in the bone mar-
row aspirate and the normalization of blood counts.
CR and PR were defined as overall remission. Relapse
was defined as marrow infiltration by more than 5% of
blast cells in previous normal bone marrow or evi-
dence of extramedullary leukemia. Patients lost to
follow-up, survived (for OS) or maintained remission
(for DFS) up to the end of the research were censored
at their date of last known contact.
Statistical analysis
Differences of the frequencies between genotypes and al-
leles in AML (remission and relapsed) patients and nor-
mal controls were evaluated using Chi-square test and
Fisher’s exact test when data were sparse. The expression
of mRNA between different genotypes of SNPs or be-
tween different genes was analyzed with t test. DFS and
OS were calculated using Kaplan-Meier estimates. A cut
off P-value of 0.05 was adopted for all statistical analyses.
Statistical significance is represented by the two-tailed
P values.
Additional files
Additional file 1: Effects of Fludarabine on cytotoxicity of Ara-C
and expression of genes involved in Ara-C metabolism and transport
in vitro. a, IC50 of HL60 and Ara-C resistant HL60 cell line (HL60R). IC50
of Ara-C in HL60 was (0.15±0.1)μg/ml, and IC50 of Ara-C in HL60R was
(47.87±4.02) μg/ml, P=0.002. b, effects of fludarabine on the cytotoxicity
of Ara-C in HL60R cell line. After incubation with fludarabine (20μg/ml)
and/or Ara-C (800μg/ml) for 24 hours, cell number was counted using
Trypan-blue to exclude dead cells. *^&$#+@ indicate statistically
significant (P<0.05).c, relative mRNA expression of DCK, CDA, 5-NT,
RRM1, RRM2 and SLC29A1 in HL60 and HL60R cells after 24-hour incubation
with Flu and/or Ara-C. mRNA was detected by real time quantitative PCR, and
β-actin was used an an internal control. *^&#+@ indicate statistically
significant (P<0.05).
Additional file 2: Genotype/allele frequencies of 19 SNPs of DCK,
CDA and SLC29A1 in healthy control and AML patients. a, b, c
showed genotype frequencies of 19 SNPs of DCK, CDA and SLC29A1; d, e, f
showed allele frequencies of 19 SNPs of DCK, CDA and SLC29A1. No significant
difference of genotype/allele frequencies was observed between the AMLpatients and healthy controls. Genotype frequencies of the 18 SNPs except
SNP15 (only one genotype in AML patients and normal donors) were found to
be in Hardy-Weinberg equilibrium (χ2 = 0.002-3.590, P =0.580-0.960).
Additional file 3: Univariate analysis of gender, age, FAB
classification on DFS and OS of patients with AML. a, Effect of age on
OS and DFS; b, effect of gender on OS and DFS; c, effect of FAB
classification on OS and DFS.
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